Other blood biomarkers that could be elevated in the preclinical stage of dementia, such as insulin [45], fibroblast growth factor 21 [26], lipocalin-2 [46], or trimethylamine N-oxide [47] may need to be considered to help increase the discriminative properties. The gene discussed is FGF21; the disease is dementia.